BRAF and cancer: BRAF is a downstream molecule of KRAS. Although more than 40 somatic mutations in the BRAF kinase domain have been described, the most common mutation across various cancers is the classic GTG → GAG substitution at the position 1799 of exon 15, which results in the V600E amino acid change, and the subsequent constitutive activation of the EGFR signalling pathway.